Document is current
Any future updates will be listed below
-
Authors
Borcherding, Nicholas
Vishwakarma, Ajaykumar https://orcid.org/0000-0003-0823-2933
Voigt, Andrew P.
Bellizzi, Andrew
Kaplan, Jacob https://orcid.org/0000-0001-8770-485X
Nepple, Kenneth
Salem, Aliasger K. https://orcid.org/0000-0002-1923-6633
Jenkins, Russell W. https://orcid.org/0000-0001-6110-2148
Zakharia, Yousef https://orcid.org/0000-0001-9480-2626
Zhang, Weizhou https://orcid.org/0000-0002-8236-0346
- License Information
-
More Information
Article History
Received: 4 December 2019
Accepted: 17 December 2020
First Online: 27 January 2021
Competing interests
: R.W.J. has a financial interest in XSphera Biosciences Inc., a company focused on using ex vivo profiling technology to deliver functional, precision immune-oncology solutions for patients, providers, and drug development companies. R.W.J. interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. Y.Z. is on the advisory board of Amgen, Roche Diagnostics, Novartis, Janssen, Eisai, Exelixis, Castle Bioscience, Array, Bayer, Pfizer, Clovis, and EMD Serono. Y.Z. has received institutional clinical trial support from NewLink Genetics, Pfizer, Exelixis, and Eisai. These associations are not related to the work herein described in the paper. Other authors declare no competing interests.
